The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruth M. Rothstein CORE Center
• Collaborators: Health Resources and Services Administration (HRSA); The New York Academy of Medicine
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Methadone; Naloxone

Criteria

Inclusion Criteria:

• 18 years or older

• Patient of the CORE Center

• HIV-infected (confirmed by HIV assay results)

• Opioid-dependent (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR] criteria)

• Fluent in English or Spanish

• Planning to stay in Chicago area for the next 12 months

Exclusion Criteria:

• Liver function tests (LFTs) (transaminase only) at 5 times or higher than normal

• DSM-IV-TR criteria for benzodiazepine abuse or dependence within the past 6 months

• DSM-IV-TR criteria for alcohol dependence within the past 6 months or actively suicidal

• Psychiatric impairment that impedes ability to consent

• Methadone dose exceeds level allowing for safe transition to buprenorphine

• Pregnant women or women actively trying to become pregnant

• Clinical judgement that patient is inappropriate for medical or psychiatric reasons